{"product_id":"vmd-vrio-analysis","title":"Viemed Healthcare, Inc. (VMD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Viemed Healthcare, Inc. (VMD)'s enduring success starts here: this VRIO analysis distills whether its core assets are truly Valuable, Rare, Inimitable, and Organized to secure a sustainable competitive advantage. Don't just guess at their market position - read on below for the definitive, high-impact summary of what truly sets them apart.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 1. Diversified In-Home Service Portfolio\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Viemed Healthcare, Inc.’s move to become more than just a respiratory player. The core takeaway here is that their recent diversification, specifically adding maternal health via the Lehan's acquisition, is a deliberate strategy to smooth out revenue risk across the care continuum. It’s a smart play, but the real test is execution.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Capturing the Care Continuum\u003c\/h3\u003e\n\u003cp\u003eThis portfolio lets Viemed Healthcare capture patients from acute needs, like Non-Invasive Ventilation (NIV), all the way through chronic management with Positive Airway Pressure (PAP) therapy, and now into women's health. This breadth is valuable because it spreads reliance away from any single reimbursement stream. For instance, their sleep business is clearly firing on all cylinders, showing a 96% increase in new patient starts in Q3 2025 alone. That kind of organic momentum in a core segment helps offset any potential headwinds in the more established ventilation business, which now accounts for less than half of total revenue.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the core segments as of September 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVentilator patient count: \u003cstrong\u003e12,372\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSleep resupply patient count: \u003cstrong\u003e33,518\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e$71.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: A Unique National Mix\u003c\/h3\u003e\n\u003cp\u003eHonestly, the specific combination of an established, high-touch respiratory\/sleep platform with a newly integrated, dedicated maternal health line is relatively rare among the national-scale Home Medical Equipment (HME) providers right now in late 2025. Most competitors are either deep in respiratory or have a more fragmented approach. Viemed Healthcare paid a base price of \u003cstrong\u003e$26 million\u003c\/strong\u003e for Lehan's Medical Equipment to secure this specific mix, which signals they see a gap in the market that their peers haven't filled yet.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Time and Integration Hurdles\u003c\/h3\u003e\n\u003cp\u003eIt’s not impossible to copy, but it takes effort. Competitors can certainly acquire smaller, specialized firms like Lehan's, which generated about \u003cstrong\u003e$25.7 million\u003c\/strong\u003e in revenue in 2024. What’s hard to replicate quickly is weaving that new service line into Viemed Healthcare’s existing national clinical model and payer contracts. That integration - making the whole thing work seamlessly - takes significant time and capital investment, which acts as a moderate barrier to immediate imitation.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Active Management and Growth Trajectory\u003c\/h3\u003e\n\u003cp\u003eThe organization looks strong because they are actively managing this new mix, not just letting it sit there. The sleep segment’s acceleration, with that \u003cstrong\u003e96%\u003c\/strong\u003e jump in new patient starts in Q3 2025, shows focused execution. Furthermore, CEO Casey Hoyt has clearly signaled that maternal health, specifically breast pumps from the Lehan’s addition, is expected to be a significant growth driver in 2026. They are already leveraging their infrastructure, adding \u003cstrong\u003e2,465\u003c\/strong\u003e patients from Lehans in the quarter the deal closed. If onboarding takes 14+ days, churn risk rises.\u003c\/p\u003e\n\n\u003cp\u003eThis diversification is supported by the structure they have in place, which is reflected in their updated full-year 2025 revenue guidance of \u003cstrong\u003e$271 million to $277 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, For Now\u003c\/h3\u003e\n\u003cp\u003eRight now, the advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. The diversification is too recent - the Lehan's deal closed in Q3 2025 - to be considered a sustained competitive advantage. Viemed Healthcare has the potential for a sustained advantage if they can prove to payers that their full suite of services drives better outcomes at a lower total cost of care than fragmented providers. Success hinges on superior integration and rapid payer adoption of the entire service offering.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eService Line\u003c\/th\u003e\n\u003cth\u003eCore Metric\/Value\u003c\/th\u003e\n\u003cth\u003eStatus\/Context (as of late 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVentilation (NIV)\u003c\/td\u003e\n\u003ctd\u003ePatient Count: \u003cstrong\u003e12,372\u003c\/strong\u003e (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eCornerstone, now accounts for \u0026lt;\u003cstrong\u003e50%\u003c\/strong\u003e of revenue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep Therapy (PAP)\u003c\/td\u003e\n\u003ctd\u003eNew Starts Growth: \u003cstrong\u003e96%\u003c\/strong\u003e (Q3 2025 YoY)\u003c\/td\u003e\n\u003ctd\u003eAccelerating meaningfully; resupply surpassed rental base.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaternal Health\u003c\/td\u003e\n\u003ctd\u003eAcquisition Cost: \u003cstrong\u003e$26 million\u003c\/strong\u003e (Base)\u003c\/td\u003e\n\u003ctd\u003eNew line via Lehan's; poised for \u003cstrong\u003e2026\u003c\/strong\u003e growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 2. National Scale with Deep Payer Relationships\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A national footprint, supported by preferred contracts, allows Viemed Healthcare to negotiate better terms and ensures broad patient access across multiple states and Medicare Advantage plans.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. While scale exists in the industry, Viemed’s specific, deep relationships across its core respiratory and newly expanded segments are not easily replicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. These relationships are built on years of performance data and trust, not just balance sheet size.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. They leverage this scale to drive operational efficiency, evidenced by SG\u0026amp;A expenses declining to \u003cstrong\u003e45.7%\u003c\/strong\u003e of revenue in Q2 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Scale combined with established payer trust creates a high barrier to entry for new, smaller competitors.\u003c\/p\u003e\n\u003cp\u003eThe national scale is evidenced by Viemed serving patients across \u003cstrong\u003eall 50 states of the United States\u003c\/strong\u003e. This scale supports significant operational metrics as of June 30, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eComparison Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenues (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$63.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecord Quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e115.1%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA (Non-GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e11.5%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVentilator Patient Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12,152\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e11.4%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAP Therapy Patient Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26,260\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e51.4%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep Resupply Patient Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25,246\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e25.1%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe reliance on and relationship with major government payers is substantial, as indicated by historical revenue composition:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedicare revenue accounted for \u003cstrong\u003e43%\u003c\/strong\u003e of revenue for the year ended December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eMedicaid revenue accounted for \u003cstrong\u003e46%\u003c\/strong\u003e of revenue for the year ended December 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eViemed focuses on clear communications with insurers, especially Medicare Advantage plans, to ensure mutual understanding of coverage criteria interpretation.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 3. Technology-Enabled, High-Touch Clinical Model\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Using clinical practitioners for therapy, education, and counseling in the home (high-touch) alongside leading technologies like NIV provides superior patient outcomes, which drives reimbursement and patient retention.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eViemed High-Touch Model Data\u003c\/th\u003e\n\u003cth\u003eIndustry Benchmark\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Readmission Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20%\u003c\/strong\u003e Industry Average\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Improved Breathing\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e93%\u003c\/strong\u003e of patients\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost Savings per Patient (Study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThrough home treatment vs. in-hospital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMortality Reduction (Study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor every 6 patients placed on VMD therapy, they save a life\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many providers offer equipment; fewer integrate the clinical service layer this effectively to manage complex respiratory patients.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eLargest independent supplier of NIV in the United States.\u003c\/li\u003e\n\u003cli\u003eVentilator Patient Count (as of June 30, 2025): \u003cstrong\u003e12,152\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePAP Therapy Patient Count (as of September 30, 2025): \u003cstrong\u003e31,891\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. It requires significant investment in clinical training, compliance infrastructure, and proprietary workflow software.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eProprietary Patient Engagement Platform (PEP) facilitates 24\/7 clinical support and remote monitoring.\u003c\/li\u003e\n\u003cli\u003eNew patient starts in the sleep business grew 96% year-over-year in Q3 2025, indicating successful scaling of the model.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. This model is central to their mission of offering cost-effective, home-based care, which is key to their strategic foundation.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eLatest Reported Amount\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$71.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$224.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shareholder Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$135.5M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The clinical expertise and associated data feedback loop are hard for equipment-focused peers to copy quickly.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eNet revenues for Q1 2025 were \u003cstrong\u003e$59.1 million\u003c\/strong\u003e, a \u003cstrong\u003e17%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eNet income for Q1 2025 increased 64% year-over-year to \u003cstrong\u003e$2.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 4. High-Growth Patient Base in Core Segments\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eRapid patient volume growth signals strong market penetration and effective sales execution, directly translating to revenue. Full-year 2025 net revenue guidance is projected to be between \u003cstrong\u003e$271 million\u003c\/strong\u003e and \u003cstrong\u003e$273 million\u003c\/strong\u003e. \nThe third quarter of 2025 reported net revenues of \u003cstrong\u003e$71.9 million\u003c\/strong\u003e, a \u003cstrong\u003e24%\u003c\/strong\u003e increase year-over-year. \nThe 5-year Compound Annual Growth Rate (CAGR) for revenue is \u003cstrong\u003e23%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. While the market is growing, Viemed Healthcare’s organic growth rate is outpacing many peers, with PAP therapy patients surging \u003cstrong\u003e63.7%\u003c\/strong\u003e year-over-year by Q3 2025.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eModerate. Competitors can hire sales reps, but replicating the \u003cstrong\u003e63.7%\u003c\/strong\u003e patient growth requires the same underlying operational excellence.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eStrong. This growth is organic, meaning the existing structure is effectively scaling its core offerings without relying solely on Mergers \u0026amp; Acquisitions (M\u0026amp;A).\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. High growth attracts immediate competitive focus; maintaining it requires continuous investment.\u003c\/p\u003e\n\n\u003cp\u003eKey Q3 2025 Operational Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$71.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e24%\u003c\/strong\u003e Increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16%\u003c\/strong\u003e Increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPS (Diluted)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.09\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAdditional Growth Indicators:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePAP Therapy Patients (Q3 2025): \u003cstrong\u003e31,891\u003c\/strong\u003e, increasing \u003cstrong\u003e64%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eSleep Resupply Patient Growth (Q3 2025): \u003cstrong\u003e51%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eVentilation Revenue: Achieved double-digit, year-over-year growth for another consecutive quarter.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 PAP Therapy Patient Count: \u003cstrong\u003e26,260\u003c\/strong\u003e, a \u003cstrong\u003e51.4%\u003c\/strong\u003e increase over Q2 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 5. Sticky, High-Growth Resupply Revenue Stream\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The resupply program generates highly predictable, recurring revenue, which is less susceptible to initial equipment reimbursement volatility. PAP therapy patients increased by \u003cstrong\u003e51.4%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e26,260\u003c\/strong\u003e as of June 30, 2025. Sleep resupply patient count increased by \u003cstrong\u003e25.1%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e25,246\u003c\/strong\u003e as of June 30, 2025.\u003c\/p\u003e\n\u003cp\u003eKey Q2 2025 Financial and Operational Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet revenues for the quarter ended June 30, 2025: \u003cstrong\u003e$63.1 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e14.7%\u003c\/strong\u003e over Q2 2024.\u003c\/li\u003e\n\u003cli\u003eNet income attributable to Viemed: \u003cstrong\u003e$3.2 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e115.1%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA for the quarter: \u003cstrong\u003e$14.3 million\u003c\/strong\u003e, an \u003cstrong\u003e11.5%\u003c\/strong\u003e increase.\u003c\/li\u003e\n\u003cli\u003eVentilator patient count: \u003cstrong\u003e12,152\u003c\/strong\u003e as of June 30, 2025, an increase of \u003cstrong\u003e11.4%\u003c\/strong\u003e over June 30, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many HME companies have resupply, but Viemed’s program is now surpassing its PAP rental base, indicating superior patient stickiness.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can offer resupply, but Viemed’s integration with its clinical service model makes its offering more compelling.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The company is organized to transition patients from therapy to resupply efficiently, which strengthens the recurring revenue model.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Value\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenue (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$63.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAP Therapy Patients (as of 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26,260\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e51.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep Resupply Patients (as of 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25,246\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The recurring nature, once established, is a durable feature of the business model.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 6. Proven M\u0026amp;A Integration Capability\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe successful acquisition and integration of Lehan's Medical Equipment in 2025 for a base price of \u003cstrong\u003e$26 million\u003c\/strong\u003e demonstrates the ability to execute diversification strategies effectively. Lehan generated net revenues of approximately \u003cstrong\u003e$25.7 million\u003c\/strong\u003e in 2024, compared to Viemed's total net revenues of \u003cstrong\u003e$224.3 million\u003c\/strong\u003e for the year ended December 31, 2024.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. Many healthcare acquisitions fail due to poor integration; Viemed is showing it can absorb new capabilities like women's health, evidenced by Lehan's 2024 Adjusted EBITDA of approximately \u003cstrong\u003e$7.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eDifficult. It requires a specific internal team, legal structure, and cultural alignment to successfully bolt-on acquisitions. The integration involves absorbing Lehan's more than \u003cstrong\u003e90\u003c\/strong\u003e employees.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eStrong. They are already anticipating updating their \u003cstrong\u003e2025\u003c\/strong\u003e guidance to reflect Lehan's contribution when reporting earnings for the quarter ended June 30, \u003cstrong\u003e2025\u003c\/strong\u003e, showing proactive financial management post-close.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. Success in one deal doesn't guarantee success in the next, but it builds a valuable organizational muscle, as seen in the prior HMP acquisition for approximately \u003cstrong\u003e$29 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe following table compares key metrics from the Lehan acquisition to the prior HMP acquisition:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLehan's Medical Equipment Acquisition (2025)\u003c\/th\u003e\n\u003cth\u003eHMP Acquisition (2023)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBase Purchase Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$29 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Contingent Payments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated as contingent in the same manner\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquired Entity 2024\/2022 Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$25.7 million\u003c\/strong\u003e (2024)\u003c\/td\u003e\n\u003ctd\u003ec. \u003cstrong\u003e$28 million\u003c\/strong\u003e (FY'22)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquired Entity Adj. EBITDA\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.4 million\u003c\/strong\u003e (2024)\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eViemed's operational expansion through M\u0026amp;A includes the following geographical and service data points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLehan adds \u003cstrong\u003e6\u003c\/strong\u003e new locations across Illinois and Wisconsin (\u003cstrong\u003e3\u003c\/strong\u003e full-service, \u003cstrong\u003e3\u003c\/strong\u003e sleep\/CPAP set-up).\u003c\/li\u003e\n\u003cli\u003eThe HMP acquisition expanded reach into Tennessee, Alabama, and Mississippi.\u003c\/li\u003e\n\u003cli\u003eViemed's Q1 2025 results showed a \u003cstrong\u003e17%\u003c\/strong\u003e increase in net revenues year-over-year.\u003c\/li\u003e\n\u003cli\u003eViemed's sleep segment accounted for \u003cstrong\u003e17%\u003c\/strong\u003e of total revenue as of Q4 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 7. Favorable Regulatory Alignment (NCD Rule)\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe final National Coverage Determination (NCD) for noninvasive home mechanical ventilators (HMV) and respiratory assist devices (RADs) was finalized by CMS on \u003cstrong\u003eJune 9, 2025\u003c\/strong\u003e. This NCD removes the requirement for patients to 'try and fail' on another device before qualifying for an HMV, allowing coverage upon discharge from the hospital. This immediately improves patient access for Viemed Healthcare’s core business, which is heavily weighted toward ventilation services.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVentilation Business Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e54%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVentilator Patient Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11,809\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Medicaid Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVentilator Monthly Rental Revenue Share\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e56%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThe NCD itself is an external factor, but Viemed’s demonstrated preparedness and prior advocacy for this specific regulatory outcome is rare among competitors. Viemed’s Chief Medical Officer, Dr. William Frazier, publicly acknowledged the NCD as a \u003cstrong\u003e'win'\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eNot Applicable (External Factor). However, the internal capability to rapidly capitalize on the rule change, as evidenced by their engaged clinical teams, is an internal capability that may be difficult to imitate quickly.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe organization is positioned to benefit as smaller operators may struggle with the new billing requirements that follow the initial six months of therapy. The company’s clinical teams are fully engaged to ensure readiness and compliance with the new guidelines.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company increased its ventilator patient count by \u003cstrong\u003e13%\u003c\/strong\u003e year-over-year as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company increased its PAP therapy patient count by \u003cstrong\u003e46%\u003c\/strong\u003e year-over-year as of March 31, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe regulatory tailwind provides a significant near-term lift, though it is considered \u003cstrong\u003eTemporary\u003c\/strong\u003e as such external factors eventually normalize across the industry.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 8. Operational Efficiency and Margin Discipline\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to grow revenue while maintaining or improving margins, leading to strong operating cash flow.\u003c\/p\u003e\n\u003cp\u003eAdjusted EBITDA guidance for the full year 2025 is set at \u003cstrong\u003e$60 million to $62 million\u003c\/strong\u003e. For the third quarter of 2025, Adjusted EBITDA reached \u003cstrong\u003e$16.1 million\u003c\/strong\u003e, representing a \u003cstrong\u003e16%\u003c\/strong\u003e increase year-over-year.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many peers face margin compression; Viemed’s \u003cstrong\u003e22.7%\u003c\/strong\u003e EBITDA margin in Q2 2025 shows discipline. The margin for Q3 2025 was reported at \u003cstrong\u003e22.4%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. This comes from leveraging fixed costs across a growing patient base and disciplined SG\u0026amp;A management.\u003c\/p\u003e\n\u003cp\u003ePatient volume growth demonstrates scale leverage:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVentilator patient count increased \u003cstrong\u003e11.4%\u003c\/strong\u003e year-over-year as of June 30, 2025, reaching \u003cstrong\u003e12,152\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePAP therapy patient count increased \u003cstrong\u003e51.4%\u003c\/strong\u003e year-over-year as of June 30, 2025, reaching \u003cstrong\u003e26,260\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSleep resupply patient count increased \u003cstrong\u003e25.1%\u003c\/strong\u003e year-over-year as of June 30, 2025, reaching \u003cstrong\u003e25,246\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. They are actively managing expenses, with SG\u0026amp;A declining as a percentage of revenue, showing they are leveraging investments.\u003c\/p\u003e\n\u003cp\u003eFor the third quarter of 2025, SG\u0026amp;A expenses were reported at \u003cstrong\u003e$31.9 million\u003c\/strong\u003e, and as a percentage of revenue, SG\u0026amp;A improved to \u003cstrong\u003e44.4%\u003c\/strong\u003e, down from \u003cstrong\u003e46.0%\u003c\/strong\u003e in the previous year.\u003c\/p\u003e\n\u003cp\u003eKey Operational and Efficiency Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$71.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e24%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e57.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease from \u003cstrong\u003e59.3%\u003c\/strong\u003e in prior year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStrong result given investments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow (Trailing 12 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Operational rigor is a deeply embedded cultural trait, not easily copied by less disciplined management teams.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViemed Healthcare, Inc. (VMD) - VRIO Analysis: 9. Established, Multi-Generational Brand Equity (via Acquisition)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The acquired Lehan's Medical Equipment brings nearly \u003cstrong\u003e80 years\u003c\/strong\u003e of brand recognition and community trust in its operating areas, which is invaluable in local healthcare markets. Lehan's was founded in \u003cstrong\u003e1946\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Viemed’s own brand is established (since 2006), but the addition of a legacy brand like Lehan's provides instant local credibility. The acquisition cost was a base purchase price of \u003cstrong\u003e$26 million\u003c\/strong\u003e plus an estimated \u003cstrong\u003e$2.2 million\u003c\/strong\u003e in contingent payments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Brand equity built over decades cannot be bought overnight; it requires time and consistent local service. Lehan generated approximately \u003cstrong\u003e$25.7 million\u003c\/strong\u003e in net revenues in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The challenge is successfully merging the legacy brand identity with Viemed’s national platform without alienating local trust. Viemed's Q3 2025 Net Revenue was \u003cstrong\u003e$71.9 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Local trust in healthcare services is a slow-to-build, hard-to-break asset.\u003c\/p\u003e\n\u003cp\u003eThe integration of Lehan's, which was completed on July 1, 2025, is expected to contribute to Viemed's financial performance, with the acquisition being immediately accretive to earnings.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003ctd\u003eYoY Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$71.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+24.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+15.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets (as of Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$202.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational metrics reflect momentum across Viemed's patient base following the acquisition period:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePAP therapy patients: \u003cstrong\u003e31,891\u003c\/strong\u003e, representing a \u003cstrong\u003e63.7%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eVentilator patients: \u003cstrong\u003e12,372\u003c\/strong\u003e, representing an \u003cstrong\u003e8.8%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eSleep resupply patients: \u003cstrong\u003e33,518\u003c\/strong\u003e, representing a \u003cstrong\u003e51.4%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eEarnings Per Share (EPS): \u003cstrong\u003e$0.09\u003c\/strong\u003e per diluted share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eViemed's full-year 2025 guidance projects net revenues between \u003cstrong\u003e$271 million\u003c\/strong\u003e and \u003cstrong\u003e$273 million\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516276138133,"sku":"vmd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vmd-vrio-analysis.png?v=1740229224","url":"https:\/\/dcf-model.com\/es\/products\/vmd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}